Latest News and Press Releases

Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors Leading expert in lipidology to support Silence as it advances new approach to treating cardiovascular disease with lead...

Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences 5 January 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in...

Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 Pre-clinical safety data show no adverse or...

Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team       –        Dr. Lindholm’s appointment reflects the Company’s commitment to maximise the siRNA...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE...

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference 1 October 2020 LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) (“Silence” or “the...

Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer Experienced biotech executive to lead the next phase of growth 14 September 2020 LONDON, Silence Therapeutics...

Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020 14 September 2020 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Group”), a leader in...

Silence Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs 8 September 2020 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or...

Silence Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares 8 September 2020 LONDON, Silence Therapeutics plc,...